98883-94-4

Basic information

• Product Name: benzophenone O-(2-morpholin-4-yl-ethyl)-oxime
• Synonyms: benzophenone O-(2-morpholin-4-yl-ethyl)-oxime
• CAS NO: 98883-94-4
• Molecular Weight: 310.396
• Mol File: 98883-94-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: benzophenone O-(2-morpholin-4-yl-ethyl)-oxime(CAS DataBase Reference)
• NIST Chemistry Reference: benzophenone O-(2-morpholin-4-yl-ethyl)-oxime(98883-94-4)
• EPA Substance Registry System: benzophenone O-(2-morpholin-4-yl-ethyl)-oxime(98883-94-4)

Safety Data

• Hazardous Substances Data: 98883-94-4(Hazardous Substances Data)

Upstream product

• 574-66-3 Benzophenone oxime 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 3240-94-6 N-(2-chlorethyl)morpholine 

Downstream Products

• 1195-51-3 O-(2-morpholinoethyl)hydroxylamine dihydrochloride 

Relevant articles and documents

Aryl oxime compounds and preparation and application thereof

The invention relates to aryl oxime compounds as shown in a general formula I, pharmaceutically acceptable salts, esters or hydrates of the aryl oxime compounds and preparation and application thereof. According to the compounds, R1 and R2 are independent

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R3, B, Z, Q, p, q and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

AMINOPYRIMIDINES AS KINASE MODULATORS

The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, Q, p, q and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.